Keyphrases
Non-Hodgkin Lymphoma
100%
Leukemia-lymphoma
100%
Acute Lymphoblastic Leukemia
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Lymphoma Patients
100%
Head-to-head Comparison
100%
CD19 chimeric Antigen Receptor T Cells
100%
Tumor-infiltrating Lymphocytes
30%
Leukemia Patients
30%
Nave
23%
CD28
15%
Relapsed or Refractory Acute Myeloid Leukemia
15%
Relapsed or Refractory
15%
Lymphocyte Infusion
15%
T Cells
7%
Young Age
7%
Positive Impact
7%
Adult Patients
7%
Solid Tumors
7%
Programmed Death-ligand 1 (PD-L1)
7%
High-level Expression
7%
Clinical Trials
7%
Response Rate
7%
Trial Registration
7%
Peripheral Blood Mononuclear Cells
7%
Clinical Response
7%
Cell-derived
7%
Cryopreserved
7%
Pediatric Patients
7%
Proliferation Rate
7%
Remission Rate
7%
Adoptive Cell Therapy
7%
Overall Response Rate
7%
Memory T Cells
7%
Clinical Deterioration
7%
Tim-3
7%
Cell Infusion
7%
C-C Chemokine Receptor Type 5 (CCR5)
7%
Target Dose
7%
Heavily Pretreated
7%
Central Memory T Cells
7%
In-house Production
7%
Chemokine Receptor CXCR3
7%
High Efficiency
7%
Proliferation Ability
7%
Solid Tumor Therapy
7%
Co-stimulatory Domain
7%
Production Failures
7%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Acute Lymphoblastic Leukemia
100%
Chimeric Antigen Receptor T-Cell
100%
Tumor Infiltrating Lymphocyte
30%
Infusion
30%
T Cell
23%
Chimeric Antigen Receptor
23%
Solid Malignant Neoplasm
15%
Deterioration
7%
Clinical Trial
7%
Cell Therapy
7%
Pediatrics
7%
Spontaneous Remission
7%
Memory T Cell
7%
Chemokine Receptor CXCR3
7%
Peripheral Blood Mononuclear Cell
7%
Immunology and Microbiology
CD19
100%
Chimeric Antigen Receptor T-Cell
100%
Tumor-Associated Macrophage
30%
Chimeric Antigen Receptor
23%
T Cell
23%
CD28
15%
Memory T Cell
7%
Peripheral Blood Mononuclear Cell
7%
Chemokine Receptor CXCR3
7%
CCR5
7%